MedEnrich | Página principal
Continue Watching
últimos vidéos
últimos vidéos
Brightcove Home Latest Listing
Cáncer de mama
Cáncer de mama
Brightcove Cards Listing
Cáncer de próstata
Brightcove Cards Listing
Mieloma múltiple
Mieloma múltiple
Brightcove Cards Listing
Popular en MedEnrich
Popular in Sin nombre
Myelodysplastic Syndromes3m 14s
Low Risk MDS - Key Practice Points
Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
ipss -m
low risk
molecular features
1
Low Risk MDS - Key Practice Points
Cáncer de mama11m 28s
ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer
ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
aromatase inhibitor resistance
hr +ve mbc
esr1 mutation
fulvestrant
1
ESR1 Mutation in Hormone Receptor Positive Advanced...
Cáncer de mama3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
tumor-infiltrating lymphocytes (tils)
promising biomarker
1
Tumor Infiltrating Lymphocytes as Predictive...
Myelodysplastic Syndromes4m 0s
Selecting Right Patients for Early Initiation in HMAs in Low Risk MDS
Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.
hypomethylating agents (hmas)
disease progression
personalised treatment plans
low risk mds
1
Selecting Right Patients for Early Initiation in...
Mieloma múltiple13m 11s
Management of Infections in Multiple Myeloma
Risk of infections in multiple myeloma has increased with the use of Novel treatments like Proteosome inhibitors, CD38 targeting MABs & BCMA targeted drugs.
prophylaxis
infections
vaccination
myeloma
1
Management of Infections in Multiple Myeloma
Mieloma múltiple7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
minimum residual disease (mrd)
mrd negativity
multiple myeloma
1
MRD Assesment in Multiple Myeloma -Ready for Prime...
Cáncer de mama8m 46s
Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer
Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
anti-her2 directed therapy
her2-positive metastatic breast cancer
expert perspective
algorithm for management of her2 positive mbc
1
Expert Perspective - How I Treat Metastatic Her2...
Myelodysplastic Syndromes5m 42s
Integrating Molecular Prognositic Systems in Management of MDS
Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.
molecular prognostic systems
ipss-m
prediction of disease progression
1
Integrating Molecular Prognositic Systems in...
Cáncer de mama8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
trastuzumab-deruxtecan (t-dxd)
her2 low breast cancers
1
Understanding HER-2 Low Breast Cancer Entity &...
Myelodysplastic Syndromes2m 25s
Factors that influence treatment adherence and outcomes in MDS
Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.
adverse events
hypomethylating agents
mds
treatment compliance
1
Factors that influence treatment adherence and...
Seminarios web anteriores
Seminarios web anteriores
Webinar Cards Listing
Artículos
Artículos
Medbytes Cards Listing
Iniciar sesión
Por favor inicie sesión para acceder a todo el contenido de MedEnrich
¿Es nuevo/a en MedEnrich? Regístrese ahora